Legal & General Group PLC Bio Atla, Inc. Transaction History

Legal & General Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$2.83 - $3.87 $11,996 - $16,404	4,239 New	4,239 $12,000
Q2 2022 Aug 22, 2022	SELL	$2.13 - $5.38 $13,131 - $33,167	-6,165 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.38 - $18.78 $398 - $1,708	91 Added 1.5%	6,165 $31,000
Q3 2021 Nov 15, 2021	BUY	$29.44 - $43.74 $141,547 - $210,301	4,808 Added 379.78%	6,074 $179,000
Q2 2021 Aug 12, 2021	BUY	$38.07 - $56.17 $2,893 - $4,268	76 Added 6.39%	1,266 $54,000
Q1 2021 May 17, 2021	BUY	$32.41 - $70.91 $6,157 - $13,472	190 Added 19.0%	1,190 $60,000
Q4 2020 Feb 12, 2021	BUY	$31.02 - $35.16 $31,020 - $35,160	1,000 New	1,000 $34,000

22.1M

10.7K

7.4K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $59.2M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.